Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Bibliographic Details
Published in:	Lancet Oncology Vol. 27; no. 8; pp. 941 - 959
Main Authors:	Turner, Nicholas C, Mayer, Erica L, Park, Yeon Hee, Janni, Wolfgang, Ma, Cynthia, Cristofanilli, Massimo, Bianchini, Giampaolo, Kalinsky, Kevin, Iwata, Hiroji, Chia, Stephen, Brufsky, Adam M, Fasching, Peter A, Nowecki, Zbigniew, Pascual, Javier, Karadurmus, Nuri, Gal-Yam, Einav, Chung, Wei-Pang, Im, Seock-Ah, Zambelli, Alberto, Dalenc, Florence
Format:	Journal Article
Published:	Elsevier B.V. Aug2026
Online Access:	View this record in EBSCOhost

Internet